-

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit.

Suarez will lead the execution of the Company’s previously announced $50 billion US research, development and manufacturing investment, including construction of a $4.5 billion manufacturing facility in Virginia, AstraZeneca’s largest single manufacturing investment globally.

The investment underpins AstraZeneca’s goal of generating $80 billion in Total Revenue by 2030, with half expected to come from the US, the Company’s largest market.

Suarez said: “We are operating at a moment of unprecedented scientific opportunity. Our responsibility is to translate that science into results for patients and for the US healthcare system. By strengthening our US manufacturing and R&D footprint, we will expand access to innovative medicines, create highly skilled jobs, and deliver long-term value.”

Suarez will have full responsibility for AstraZeneca’s US BioPharmaceuticals organization, with accountability for performance, growth and execution across the portfolio.

Suarez brings more than 20 years of experience in the US healthcare sector, with leadership roles spanning commercial, medical and market access functions at AstraZeneca. He returns to the US after serving as Country President for Spain since 2020, where he led one of AstraZeneca’s strongest performing European markets. He expanded Spain’s role in global clinical development and positioned Barcelona as a strategic hub for innovation.

During his tenure in Spain, Suarez established a new global hub in Barcelona and launched the AstraZeneca Healthcare Innovation Hub, committing more than €10 million to digital health and data-driven initiatives focused on translational innovation.

Suarez will be based at AstraZeneca’s US headquarters in Wilmington, Delaware. His appointment is effective immediately.

Biographical information

Rick Suarez was born in the United States and grew up in New Haven, Connecticut. He joined AstraZeneca in 1999 as a pharmaceutical sales specialist and has worked across many functions of the business including marketing, medical affairs and market access.

Notes

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on social media @AstraZeneca.

Contacts

Media Inquiries
Fiona Cookson +1 212 814 3923

US Media Mailbox: usmediateam@astrazeneca.com

Industry:

AstraZeneca

NASDAQ:AZN
Release Versions
English

Contacts

Media Inquiries
Fiona Cookson +1 212 814 3923

US Media Mailbox: usmediateam@astrazeneca.com

More News From AstraZeneca

Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca’s sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) in 2nd- and later-line Claudin 18.2-positive advanced gastric cancers versus investigator’s choice of therapy. The trial included patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or e...

ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the US availability of ZEGFROVY® (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, and whose disease has progressed on or after platinum-based chemotherapy.1 The US Food and Drug Administration granted accelerated approval to ZEGFROVY based on res...

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to revolutionize cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October 23-27, 2026. More than 100 abstracts will be presented, including data from five pivotal Phase III trials, four of which will be featured in Presidential Symposia. This breadth of data will demonstrate how AstraZeneca is redefining the way cancer is treated...
Back to Newsroom